Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS: Apalutamide plus ADT before and after RP cuts metastasis risk
2
Pedro Barata, MD, highlights phase 3 data on 177Lu-rosopatamab tetraxetan in mCRPC
3
Tanya B. Dorff, MD, highlights early data on ABBV-969 in mCRPC
4
Perioperative Therapy Expansion in Cisplatin-Ineligible MIBC
5